A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer

被引:241
作者
Braunstein, Steve
Karpisheva, Ksenia
Pola, Carolina
Goldberg, Judith
Hochman, Tsivia
Yee, Herman
Cangiarella, Joan
Arju, Rezina
Formenti, Silvia C.
Schneider, Robert J. [1 ]
机构
[1] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA
[2] NYU, Sch Med, Div Biostat, Dept Environm Med, New York, NY 10016 USA
[3] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[4] NYU, Sch Med, Inst Canc, New York, NY 10016 USA
关键词
D O I
10.1016/j.molcel.2007.10.019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Translational regulation is critical in cancer development and progression. Translation sustains tumor growth and development of a tumor vasculature, a process known as angiogenesis, which is activated by hypoxia. Here we first demonstrate that a majority of large advanced breast cancers overexpress translation regulatory protein 4E-BP1 and initiation factor elF4G. Using model animal and cell studies, we then show that overexpressed 4E-BP1 and elF4G orchestrate a hypoxia-activated switch from cap-dependent to cap-independent mRNA translation that promotes increased tumor angiogenesis and growth at the level of selective mRNA translation. Elevated levels of 4E-BP1 trigger hypoxia inhibition of cap-dependent mRNA translation at high-oxygen levels and, with eIF4G, increase selective translation of mRNAs containing internal ribosome entry sites (IRESs) that include key proangiogenic, hypoxia, and survival mRNAs. The switch from cap-dependent to cap-independent mRNA translation facilitates tumor angiogenesis and hypoxia responses in animal models.
引用
收藏
页码:501 / 512
页数:12
相关论文
共 35 条
  • [1] Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells
    Avdulov, S
    Li, S
    Michalek, V
    Burrichter, D
    Peterson, M
    Perlman, DM
    Manivel, JC
    Sonenberg, N
    Yee, D
    Bitterman, PB
    Polunovsky, VA
    [J]. CANCER CELL, 2004, 5 (06) : 553 - 563
  • [2] Barbe Esther, 1996, MEDITERR POLIT, V1, P25
  • [3] Tumorigenesis and the angiogenic switch
    Bergers, G
    Benjamin, LE
    [J]. NATURE REVIEWS CANCER, 2003, 3 (06) : 401 - 410
  • [4] INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS
    BROOKS, PC
    MONTGOMERY, AMP
    ROSENFELD, M
    REISFELD, RA
    HU, TH
    KLIER, G
    CHERESH, DA
    [J]. CELL, 1994, 79 (07) : 1157 - 1164
  • [5] Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer
    Castellvi, Josep
    Garcia, Angel
    Rojo, Federico
    Ruiz-Marcellan, Carmen
    Gil, Antonio
    Baselga, Jose
    Ramon y Cajal, Santiago
    [J]. CANCER, 2006, 107 (08) : 1801 - 1811
  • [6] Hypoxia-induced vascular endothelial growth factor transcription and protection from apoptosis are dependent on α6β1 integrin in breast carcinoma cells
    Chung, J
    Yoon, S
    Datta, K
    Bachelder, RE
    Mercurio, AM
    [J]. CANCER RESEARCH, 2004, 64 (14) : 4711 - 4716
  • [7] Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells
    Connolly, Eileen
    Braunstein, Steve
    Formenti, Silvia
    Schneider, Robert J.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (10) : 3955 - 3965
  • [8] Antianglogenic potential of the mammalian target of rapamycin inhibitor temsirolimus
    Del Bufalo, Donatella
    Ciuffreda, Ludovica
    Triscinoglio, Daniela
    Desideri, Marianna
    Cognetti, Francesco
    Zupi, Gabriella
    Milella, Michele
    [J]. CANCER RESEARCH, 2006, 66 (11) : 5549 - 5554
  • [9] eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation
    Gingras, AC
    Raught, B
    Sonenberg, N
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 : 913 - 963
  • [10] Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
    Guba, M
    von Breitenbuch, P
    Steinbauer, M
    Koehl, G
    Flegel, S
    Hornung, M
    Bruns, CJ
    Zuelke, C
    Farkas, S
    Anthuber, M
    Jauch, KW
    Geissler, EK
    [J]. NATURE MEDICINE, 2002, 8 (02) : 128 - 135